{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:16:11Z","timestamp":1792167371690,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacl.2026.03.026","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T23:33:09Z","timestamp":1775604789000},"page":"1339-1351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The association between remnant cholesterol and cardiovascular events: A systematic review and meta-regression"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-5154","authenticated-orcid":false,"given":"Paula","family":"Byrne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7865-5062","authenticated-orcid":false,"given":"Trevor","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne","family":"Demasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Saif-Ur-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dubroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacl.2026.03.026_bib1","first-page":"3826","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"25","author":"Mach","year":"2020","journal-title":"Russ\u00a0J\u00a0Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2026.03.026_bib2","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.03.026_bib3","article-title":"Systemic consequences of abnormal cholesterol handling: Interdependent pathways of inflammation and dyslipidemia","volume":"13","author":"O\u2019Hagan","year":"2022","journal-title":"Front\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.026_bib4","first-page":"263","article-title":"Association of mean platelet volume and red blood cell distribution width with coronary collateral development in stable coronary artery disease","volume":"14","author":"Sincer","year":"2018","journal-title":"Post\u0119py\u00a0Kardiol\u00a0Interwencyjnej"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.026_bib5","first-page":"145","article-title":"A novel marker for prediabetic conditions: Uric acid-to-HDL cholesterol ratio","volume":"125","author":"Balci","year":"2024","journal-title":"Bratisl\u00a0Lek\u00a0Listy"},{"key":"10.1016\/j.jacl.2026.03.026_bib6","article-title":"Waist-to-height ratio as a novel marker of metabolic syndrome in patients with type 2 diabetes mellitus","volume":"2","author":"Basaran","year":"2025","journal-title":"Explor\u00a0Endocr\u00a0Metab\u00a0Dis"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.026_bib7","first-page":"111","article-title":"Evaluation of the effects of intermittent fasting on clinical and laboratory parameters in metabolic syndrome","volume":"8","author":"Duman","year":"2025","journal-title":"Exp\u00a0Biomed\u00a0Res"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.026_bib8","first-page":"247","article-title":"The systemic immune inflammation index is a reliable and novel risk factor for metabolic dysfunction-associated fatty liver disease","volume":"41","author":"Kosekli","year":"2025","journal-title":"Curr\u00a0Med\u00a0Res\u00a0Opin"},{"issue":"1206","key":"10.1016\/j.jacl.2026.03.026_bib9","first-page":"342","article-title":"Systemic inflammatory markers and epicardial fat volume as predictors of cardiometabolic risk in type 2 diabetes","volume":"102","author":"Cosgun","year":"2026","journal-title":"Postgrad\u00a0Med\u00a0J"},{"issue":"42","key":"10.1016\/j.jacl.2026.03.026_bib10","first-page":"4333","article-title":"Keeping remnants in perspective","volume":"42","author":"Bor\u00c9n","year":"2021","journal-title":"Eur\u00a0Heart J"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.026_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.121.012615","article-title":"Remnant cholesterol: the leftovers and their contribution to atherosclerotic cardiovascular disease","volume":"14","author":"Bruemmer","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"42","key":"10.1016\/j.jacl.2026.03.026_bib12","first-page":"4324","article-title":"Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study","volume":"42","author":"Quispe","year":"2021","journal-title":"Eur\u00a0Heart J"},{"issue":"34","key":"10.1016\/j.jacl.2026.03.026_bib13","first-page":"3258","article-title":"Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study","volume":"43","author":"Wadstr\u00d6m","year":"2022","journal-title":"Eur\u00a0Heart J"},{"issue":"47","key":"10.1016\/j.jacl.2026.03.026_bib14","first-page":"4833","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur\u00a0Heart J"},{"issue":"24","key":"10.1016\/j.jacl.2026.03.026_bib15","first-page":"1826","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2012","journal-title":"Eur\u00a0Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.026_bib16","first-page":"6","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat\u00a0Rev\u00a0Methods Primers"},{"issue":"47","key":"10.1016\/j.jacl.2026.03.026_bib17","first-page":"4791","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur\u00a0Heart J"},{"key":"10.1016\/j.jacl.2026.03.026_bib18","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4","author":"Higgins","year":"2023"},{"key":"10.1016\/j.jacl.2026.03.026_bib19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2026.03.026_bib20","unstructured":"Byrne P., Jones M., Demasi M., Lin T., Saif-Ur-Rahman K.M., Dubroff R. A comparison of the association between non-HDL and remnant cholesterol and cardiovascular events: protocol for a systematic review and meta-analysis. PROSPERO CRD42023488423; 2023. (accessed 17\/07\/2025) https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023488423."},{"key":"10.1016\/j.jacl.2026.03.026_bib21","unstructured":"Covidence systematic review software VHI, Melbourne, Australia. (accessed 17\/07\/2025) www.covidence.org."},{"key":"10.1016\/j.jacl.2026.03.026_bib22","unstructured":"Microsoft Excel Version 2406; 2024. (accessed 17\/07\/2025) https:\/\/www.microsoft.com\/en-ie\/microsoft-365\/excel?legRedir=true&CorrelationId=2e497c37-a7f2\u20134e16-b493-b0188745bd07."},{"key":"10.1016\/j.jacl.2026.03.026_bib23","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.026_bib24","first-page":"380","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin\u00a0Epidemiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.026_bib25","first-page":"177","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control\u00a0Clin\u00a0Trials"},{"issue":"11","key":"10.1016\/j.jacl.2026.03.026_bib26","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacl.2026.03.026_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0002-9149(84)90854-3","article-title":"Lipid research clinics coronary primary prevention trial: results and implications","volume":"54","author":"Rifkind","year":"1984","journal-title":"Am\u00a0J\u00a0Cardiol"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.026_bib28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ebiom.2015.08.006","article-title":"The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study","volume":"2","author":"Hosomi","year":"2015","journal-title":"EBioMedicine"},{"issue":"18","key":"10.1016\/j.jacl.2026.03.026_bib29","first-page":"1713","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"20","key":"10.1016\/j.jacl.2026.03.026_bib30","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"9364","key":"10.1016\/j.jacl.2026.03.026_bib31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.jacl.2026.03.026_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.026_bib33","first-page":"538","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. Journal article","volume":"161","author":"Aim-High Investigators","year":"2011","journal-title":"Am\u00a0Heart J"},{"issue":"21","key":"10.1016\/j.jacl.2026.03.026_bib34","first-page":"1923","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.03.026_bib35","first-page":"687","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N\u00a0Engl\u00a0J\u00a0Med"},{"issue":"22","key":"10.1016\/j.jacl.2026.03.026_bib36","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.026_bib37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.026_bib38","first-page":"1437","article-title":"A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis","volume":"71","author":"Kitas","year":"2019","journal-title":"Arthritis\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.026_bib39","first-page":"220","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus' usual'care in secondary coronary heart disease prevention","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr\u00a0Med\u00a0Res\u00a0Opin"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.026_bib40","first-page":"870","article-title":"Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"16","author":"Chevli","year":"2022","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.026_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacl.2025.02.014","article-title":"Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults","volume":"19","author":"Kim","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.026_bib42","first-page":"801","article-title":"Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol","volume":"9","author":"Goliasch","year":"2015","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.026_bib43","first-page":"3","article-title":"Association between remnant cholesterol and incident atherosclerotic cardiovascular disease, heart failure, and atrial fibrillation","volume":"18","author":"Tada","year":"2024","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.03.026_bib44","first-page":"e905","article-title":"Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: a post hoc analysis of the RACING trial","volume":"18","author":"Lee","year":"2024","journal-title":"J\u00a0Clin\u00a0Lipidol"},{"issue":"24","key":"10.1016\/j.jacl.2026.03.026_bib45","first-page":"1826","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur\u00a0Heart J"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.026_bib46","first-page":"427","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am\u00a0Coll\u00a0Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.03.026_bib47","first-page":"358","article-title":"Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment","volume":"141","author":"Varbo","year":"2014","journal-title":"Pharmacol\u00a0Ther"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.026_bib48","first-page":"550","article-title":"Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population","volume":"85","author":"Varbo","year":"2019","journal-title":"Ann\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.026_bib49","first-page":"207","article-title":"Causal associations of remnant cholesterol with cardiometabolic diseases and risk factors: a mendelian randomization analysis","volume":"22","author":"Guan","year":"2023","journal-title":"Cardiovasc\u00a0Diabetol"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.026_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-78610-0","article-title":"Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample mendelian randomization study","volume":"14","author":"Zhong","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.026_bib51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s12916-025-04329-y","article-title":"The causal effects of remnant cholesterol on increased risk of cardiovascular diseases in East Asians","volume":"23","author":"Lin","year":"2025","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.026_bib52","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1161\/ATVBAHA.123.319297","article-title":"Independent causal effect of remnant cholesterol on atherosclerotic cardiovascular outcomes: a Mendelian randomization study","volume":"43","author":"Navarese","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.03.026_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.09.008","article-title":"Remnant cholesterol and associations with incidence, progression, and change in coronary artery calcium in South Asian Americans","author":"Manghis","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.026_bib54","article-title":"Remnant cholesterol and common carotid artery intima-media thickness in patients with ischemic stroke","volume":"14","author":"Qian","year":"2021","journal-title":"Circ\u00a0Cardiovasc\u00a0Imaging"},{"key":"10.1016\/j.jacl.2026.03.026_bib55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jpeds.2021.01.019","article-title":"Elevated serum concentrations of remnant cholesterol associate with increased carotid intima-media thickness in children and adolescents","volume":"232","author":"Di Costanzo","year":"2021","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.026_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-2275(20)32331-2","article-title":"Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides","volume":"42","author":"Karpe","year":"2001","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacl.2026.03.026_bib57","first-page":"S377","article-title":"Association of intima-media thickness of carotid arteries with remnant lipoproteins in men and women","volume":"64","author":"Pitha","year":"2015","journal-title":"Physiol\u00a0Res"},{"key":"10.1016\/j.jacl.2026.03.026_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.08.014","article-title":"Non-HDL and LDL cholesterol, but not calculated remnant cholesterol, are associated with subclinical atherosclerosis","author":"Mickelsson","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2026.03.026_bib59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2188\/jea.JE20200305","article-title":"Exploring the causal roles of circulating remnant lipid profile on cardiovascular and cerebrovascular diseases: Mendelian randomization study","volume":"32","author":"Si","year":"2022","journal-title":"J Epidemiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.03.026_bib60","first-page":"577","article-title":"Mendelian randomization in cardiometabolic disease: challenges in evaluating causality","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat\u00a0Rev\u00a0Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.03.026_bib61","first-page":"2992","article-title":"Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: a Mendelian randomization phenome-wide association study in the UK Biobank","volume":"89","author":"Pham","year":"2023","journal-title":"Br\u00a0J\u00a0Clin\u00a0Pharmacol"},{"issue":"R2","key":"10.1016\/j.jacl.2026.03.026_bib62","first-page":"R195","article-title":"Evaluating the potential role of pleiotropy in Mendelian randomization studies","volume":"27","author":"Hemani","year":"2018","journal-title":"Hum\u00a0Mol\u00a0Genet"},{"issue":"4","key":"10.1016\/j.jacl.2026.03.026_bib63","first-page":"330","article-title":"Recent developments in Mendelian randomization studies","volume":"4","author":"Zheng","year":"2017","journal-title":"Curr\u00a0Epidemiol\u00a0Rep"},{"issue":"383","key":"10.1016\/j.jacl.2026.03.026_bib64","article-title":"The druggable genome and support for target identification and validation in drug development","volume":"9","author":"Finan","year":"2017","journal-title":"Sci Transl\u00a0Med"},{"issue":"1","key":"10.1016\/j.jacl.2026.03.026_bib65","first-page":"5640","article-title":"Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease","volume":"12","author":"Schmidt","year":"2021","journal-title":"Nat\u00a0Commun"},{"issue":"5","key":"10.1016\/j.jacl.2026.03.026_bib66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacl.2024.05.002","article-title":"Distribution of triglyceride-rich lipoproteins and their remnants and their contribution to cardiovascular risk in the Mexican population","volume":"20","author":"Cruz-Bautista","year":"2026","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2026.03.026_bib67","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"10263","key":"10.1016\/j.jacl.2026.03.026_bib68","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacl.2026.03.026_bib69","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","article-title":"Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.03.026_bib70","first-page":"1","article-title":"External validation of multivariable prediction models: a systematic review of methodological conduct and reporting","volume":"14","author":"Collins","year":"2014","journal-title":"BMC Med\u00a0Res\u00a0Methodol"},{"issue":"9841","key":"10.1016\/j.jacl.2026.03.026_bib71","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists","year":"2012","journal-title":"Lancet"},{"issue":"9753","key":"10.1016\/j.jacl.2026.03.026_bib72","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.03.026_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5038","article-title":"Statins and the BMJ","volume":"349","author":"Godlee","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2026.03.026_bib74","doi-asserted-by":"crossref","first-page":"zwaf201","DOI":"10.1093\/eurjpc\/zwaf201","article-title":"Challenges in defining, measuring, and calculating remnant cholesterol","author":"DuBroff","year":"2025","journal-title":"European Journal of Preventive Cardiology"},{"issue":"2","key":"10.1016\/j.jacl.2026.03.026_bib75","first-page":"53","article-title":"Helping doctors and patients make sense of health statistics","volume":"8","author":"Gigerenzer","year":"2007","journal-title":"Psychol\u00a0Sci\u00a0Public Interest"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426000978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:29:12Z","timestamp":1786033752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426000978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1933287426000978"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.026","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between remnant cholesterol and cardiovascular events: A systematic review and meta-regression","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}